From rheumatic fever to Libman-Sacks endocarditis: is there any possible pathogenetic link?

被引:11
作者
Blank, M
Aron-Maor, A
Shoenfeld, Y [1 ]
机构
[1] Chaim Sheba Med Ctr, Dept Internal Med B, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Laura Schwarz Kipp Chair Res Autoimmune Dis, IL-69978 Tel Aviv, Israel
关键词
anti-beta; 2GPI; antiphosphplipid syndrome; autoimmunity; Libman-Sacks endocarditis; M-protein; rheumatic fever;
D O I
10.1191/0961203305lu2203oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The heart lesions of rheumatic fever and the heart involvement in antiphospholipid syndrome (APS), have different clinical pictures. Yet, there are several common characteristics linking both diseases: 1) central nervous system (CNS) and heart involvement; 2) molecular mimicry between the a pathogen and the origin of the disease; 3) cross reacting antibodies between the pathogen and self molecules; 4) endothelial cell activation in the 'crime-area' i.e., the valves; 5) some of the patients with RF have circulating antiphospholipid antibodies, while APS may be associated with streptococcal infection; and 6) recently, a cross-reactivity between antibodies directed to the streptococcal M-protein and its synthetic derivative in rheumatic fever (RF) and antibodies derived from APS patients targeting the beta-2-glycoprotein-I (beta 2GPI) and a beta 2GPI related synthetic peptide. In the current paper, we summarize the possible links between the heart involvement in RF and APS.
引用
收藏
页码:697 / 701
页数:5
相关论文
共 38 条
[1]   Increased endothelial cell expression of α3β1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome [J].
Afek, A ;
Shoenfeld, Y ;
Manor, R ;
Goldberg, I ;
Ziporen, L ;
George, J ;
Polak-Charcon, S ;
Amigo, MC ;
Garcia-Torres, R ;
Segal, R ;
Kopolovic, J .
LUPUS, 1999, 8 (07) :502-507
[2]  
Amital H, 1999, CLIN EXP RHEUMATOL, V17, P99
[3]  
Antone SM, 1997, J IMMUNOL, V159, P5422
[4]  
ASHERSON RA, 1989, CLIN EXP RHEUMATOL, V7, P225
[5]  
Bisno AL, 1995, PRINCIPLES PRACTICE, V2, P1799
[6]   Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides [J].
Blank, M ;
Shoenfeld, Y ;
Cabilly, S ;
Heldman, Y ;
Fridkin, M ;
Katchalski-Katzir, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (09) :5164-5168
[7]   Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection [J].
Blank, M ;
Shani, A ;
Goldberg, I ;
Kopolovic, J ;
Amigo, MC ;
Magrini, L ;
Shoenfeld, Y .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :589-592
[8]   Antiphospholipid syndrome infectious origin [J].
Blank, M ;
Asherson, RA ;
Cervera, R ;
Shoenfeld, Y .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (01) :12-23
[9]   Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome [J].
Blank, M ;
Krause, I ;
Fridkin, M ;
Keller, N ;
Kopolovic, J ;
Goldberg, I ;
Tobar, A ;
Shoenfeld, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (06) :797-804
[10]   Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Cervera, R ;
Piette, JC ;
Font, J ;
Khamashta, MA ;
Shoenfeld, Y ;
Camps, MT ;
Jacobsen, S ;
Lakos, G ;
Tincani, A ;
Kontopoulou-Griva, I ;
Galeazzi, M ;
Meroni, PL ;
Derksen, RHWM ;
de Groot, PG ;
Gromnica-Ihle, E ;
Baleva, M ;
Mosca, M ;
Bombardieri, S ;
Houssiau, F ;
Gris, JC ;
Quéré, I ;
Hachulla, E ;
Vasconcelos, C ;
Roch, B ;
Fernández-Nebro, A ;
Boffa, MC ;
Hughes, GRV ;
Ingelmo, M .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027